Eli Lilly & Co. (LLY:US), saying that meeting its sale target will be a challenge, plans to repurchase $5 billion in shares and introduce new diabetes drugs to help navigate past four years of patent losses.
Less-than-expected profit in emerging markets and a decline in the yen have slowed growth across the pharmaceutical industry. That may make it more difficult for Lilly to meet a reaffirmed goal of at least $20 billion in revenue through 2014, the Indianapolis-based company said in a statement today.
The new products and buybacks are part of Lilly’s strategy to return to growth after next year. Pfizer Inc. (PFE:US), the biggest U.S. drugmaker, is splitting its businesses to offset its patent losses, while Merck & Co. earlier this week increased job cuts and refocused its research program.
“I am confident in our outlook to return to a period of growth and expanding margins,” Lilly Chief Financial Officer Derica Rice said in the statement.
Lilly reiterated goals of at least $3 billion in net income and $4 billion in operating cash flow through next year.
The company filed U.S. and European regulatory submissions for two diabetes treatments -- empagliflozin and dulaglutide -- and a European submission for a new insulin glargine product.
Lilly also is seeking approval for ramucirumab to treat advanced gastric cancer. Necitumumab, a lung-cancer medicine, performed well in a trial and the company may file for regulatory approval as early as next year, according to the statement.
Investors will keep a close eye on the pipeline, said Mark Schoenebaum, an analyst with International Strategy & Investment Group LLC in New York, in a note today.
“Will Lilly hit this guidance even if the pipeline fails?” Schoenebaum said was the question on investors’ minds. “We would like to understand if there if a ’Plan B’ exists.”
Lilly met with investors today in Indianapolis. The company’s shares (LLY:US) fell 3.4 percent to $48.80 at the close in New York, the biggest single-day decline since June 20.
“Market factors, including the devaluation of the yen and slower market growth in key emerging market countries, have moderated the company’s near-term revenue growth expectations,” Lilly said in the statement. “These headwinds will make it challenging for the company to meet the minimum revenue goal of $20 billion in 2014.”
To contact the reporters on this story: Alex Nussbaum in New York at email@example.com; Drew Armstrong in Washington at firstname.lastname@example.org
To contact the editor responsible for this story: Reg Gale at email@example.com